Clinical significance of epigenetic silencing and re-expression of o6-methylguanine-dna methyltransferase using epigenetic agents in laryngeal carcinoma

Oncology Letters

Volumn 9, Issue 1, 2015, Pages 35-42

  Yang, Jing ^a   Zhu, Xin Bing ^b   He, Li Xia ^c   Gu, Zhao Wei ^a   Jin, Ming Zhu ^a   Ji, Wen Yue ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b The Central Hospital of Liaohe Oil Field   (China)

^c Department of Otorhinolaryngology Fushun Second Hospital   (China)

Author keywords

5 aza 2' deoxycytidine; DNA methylation; Histone modification; Laryngeal carcinoma; O6 methylguanine DNA methyltransferase gene; Trichostatin A

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HISTONE H3; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TRICHOSTATIN A;

ADULT; ARTICLE; CELL INVASION ASSAY; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; GENE SILENCING; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LARYNX SQUAMOUS CELL CARCINOMA; MALE; MIGRATION INHIBITION; MRNA EXPRESSION ASSAY; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WOUND HEALING;

EID: 84911456584     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2662     Document Type: Article

References (29)

1. Marioni G, Marchese-Ragona R, Cartei G, Marchese F and Staffieri A: Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat Rev 32: 504-515, 2006.
2. Bugni JM, Meira LB and Samson LD: Alkylation-induced colon tumorigenesis in mice deficient in the Mgmt and Msh6 proteins. Oncogene 28: 734-741, 2009.
3. Meng CF, Zhu XJ, Peng G and Dai DQ: Role of histone modifications and DNA methylation in the regulation of O6-methylguanine-DNA methyltransferase gene expression in human stomach cancer cells. Cancer Invest 28: 331-339, 2010.
4. McCabe MT, Brandes JC and Vertino PM: Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res 15: 3927-3937, 2009.
5. Kim YJ, Yoon HY, Kim SK, et al: EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin Cancer Res 17: 4523-4530, 2011.
6. Chang X, Li Z, Ma J, et al: DNA methylation of NDRG2 in gastric cancer and its clinical significance. Dig Dis Sci 58: 715-723, 2013.
7. Wozniak RJ, Klimecki WT, Lau SS, Feinstein Y and Futscher BW: 5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene 26: 77-90, 2007.
8. Sharma S, Kelly TK and Jones PA: Epigenetics in cancer. Carcinogenesis 31: 27-36, 2010.
9. O'Sullivan B and Shah J: New TNM staging criteria for head and neck tumors. Semin Surg Oncol 21: 30-42, 2003.
10. Samudio-Ruiz SL and Hudson LG: Increased DNA methyltransferase activity and DNA methylation following epidermal growth factor stimulation in ovarian cancer cells. Epigenetics 7: 216-224, 2012.
11. Kondo Y, Shen L, Cheng AS, et al: Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 40: 741-750, 2008.
12. Socha MJ, Said N, Dai Y, et al: Aberrant promoter methylation of SPARC in ovarian cancer. Neoplasia 11: 126-135, 2009.
13. Wu LP, Wang X, Li L, et al: Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. Mol Cell Biol 28: 3219-3235, 2008.
14. Grewal SI and Moazed D: Heterochromatin and epigenetic control of gene expression. Science 301: 798-802, 2003.
15. Chang X, Zhang S, Ma J, et al: Association of NDRG1 gene promoter methylation with reduced NDRG1 expression in gastric cancer cells and tissue specimens. Cell Biochem Biophys 66: 93-101, 2013.
16. Agathanggelou A, Cooper WN and Latif F: Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 65: 3497-3508, 2005.
17. Fahrner, JA, Eguchi S, Herman JG and Baylin SB: Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 62: 7213-7218, 2002.
18. Liu J, Zhu X, Xu X and Dai D: DNA promoter and histone H3 methylation downregulate NGX6 in gastric cancer cells. Med Oncol 31: 817, 2014.
19. Dong W, Wang L and Shen R: MYO5B is epigenetically silenced and associated with MET signaling in human gastric cancer. Dig Dis Sci 58: 2038-2045, 2013.
20. Chakraborty AK, Sousa Jde F, Chakraborty D, et al: GnT-V expression and metastatic phenotypes in macrophage-melanoma fusion hybrids is down-regulated by 5-Aza-dC: evidence for methylation sensitive, extragenic regulation of GnT-V transcription. Gene 374: 166-173, 2006.
21. Peng DF, Razvi M, Chen H, et al: DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma. Gut 58: 5-15, 2009.
22. Fuks F, Hurd PJ, Deplus R and Kouzarides T: The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res 31: 2305-2312, 2003.
23. Lin W and Dent SY: Functions of histone-modifying enzymes in development. Curr Opin Genet Dev 16: 137-142, 2006.
24. Kondo Y: Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med J 50: 455-463, 2009.
25. Schneider BG, Peng DF, Camargo MC, et al: Promoter DNA hypermethylation in gastric biopsies from subjects at high and low risk for gastric cancer. Int J Cancer 127: 2588-2597, 2010.
26. Tost J: DNA methylation: an introduction to the biology and the disease-associated changes of a promising biomarker. Methods Mol Biol 507: 3-20, 2009.
27. Tong JD, Jiao NL, Wang YX, Zhang YW and Han F: Downregulation of fibulin-3 gene by promoter methylation in colorectal cancer predicts adverse prognosis. Neoplasma 58: 441-448, 2011.
28. Zhi Y, Chen J, Zhang S, et al: Down-regulation of CXCL12 by DNA hypermethylation and its involvement in gastric cancer metastatic progression. Dig Dis Sci 57: 650-659, 2012.
29. Hu Q, Yu L, Chen R, Wang YL, et al: 5-aza-2'-deoxycytidine improves the sensitivity of endometrial cancer cells to progesterone therapy. Int J Gynecol Cancer 22: 951-959, 2012.